<DOC>
	<DOCNO>NCT00003093</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Combination chemotherapy plus surgery may effective treatment neuroblastoma . PURPOSE : This phase III trial study well combination chemotherapy follow surgery work treat young patient neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether use select prognostic variable assign treatment increase event-free survival overall survival child intermediate-risk neuroblastoma . - Determine acute long-term morbidity toxicity surgery combination chemotherapy patient population . - Assess relationship extent tumor resection event-free overall survival patient treat regimen . OUTLINE : Patients receive carboplatin IV 1 hour day 0 , 21 , 63 ; cyclophosphamide IV 1 hour day 21 42 ; doxorubicin IV 15-60 minute day 21 63 ; etoposide IV 2 hour day 0-2 , 42-44 , 63-65 . Patients 60 day age also receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously begin 24 hour last chemotherapy administration continue blood count recover . Patients favorable biology achieve complete remission undergo surgery remove debulk residual disease day 84 blood count recover . Patients favorable biology achieve partial response surgery primary site deem best interest patient may receive additional chemotherapy ( ) delay surgery primary site completion chemotherapy . Patients unfavorable biology receive additional chemotherapy comprise cyclophosphamide IV 1 hour day 84 , 105 , 147 ; etoposide IV 2 hour day 84-86 126-128 ; carboplatin IV 1 hour day 105 126 ; doxorubicin IV 15-60 minute day 105 147 . Patients undergo debulking surgery day 168 blood count recover . Some patient may undergo radiotherapy surgery . Patients follow monthly 6 month , every 2 month 6 month , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 400 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven neuroblastoma mature ganglioneuroma judge intermediate risk one follow criterion : International Neuroblastoma Staging System ( INSS ) stage III Under 1 year old , MYCN oncogene nonamplified , ploidy 1 20 year old , MYCN nonamplified , favorable Shimada histology INSS stage IV Under 1 year old , MYCN nonamplified , ploidy INSS stage IVS Under 1 year old , MYCN nonamplified , unfavorable Shimada histology ploidy OR favorable Shimada histology diploidy All patient must register companion neuroblastoma biology study ( COGANBL00B1 ) PATIENT CHARACTERISTICS : Age : Under 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No abnormal organ function would prohibit chemotherapy unless due neuroblastoma PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy patient intradural extension emergent paresis allow provide biopsy perform within 96 hour treatment Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>